Treprostinil, sold under the brand namesRemodulin for infusion,Orenitram for oral, andTyvaso for inhalation among others, is avasodilator that is used for the treatment ofpulmonary arterial hypertension.[7]
Treprostinil was approved for use in the United States in May 2002.[8]
Treprostinil inhalation solution and treprostinil inhalation powder are indicated for the treatment of people with pulmonary arterial hypertension (WHO Group 1) to improve exercise ability; and people with pulmonary hypertension associated with interstitial lung disease (WHO Group 3) to improve exercise ability.[3][4]
In the European Union, treprostinil (Trepulmix) is indicated for the treatment of adults with WHO Functional Class III or IV and inoperable chronic thromboembolic pulmonary hypertension;[6] or persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment to improve exercise capacity.[6]
Since treprostinil is avasodilator, its antihypertensive effect may be compounded by other medications that affect the blood pressure, includingcalcium channel blockers,diuretics, and other vasodilating agents.[9]
Because of treprostinil's inhibiting effect on platelet aggregation, there is an increased risk of bleeding, especially among patients who are also takinganticoagulants.[9]
Common side effects depending on route of administration:
85% of patients report pain or other reaction at the infusion site.[9]
In 1976, the first paper on prostacyclin was published.[10]
Treprostinil (Remodulin) was approved for medical use in the United States in May 2002,[8] and again in July 2018.[11]
Treprostinil (Tyvaso), as inhalation solution, was approved for medical use in the United States in July 2009,[12] and again in April 2021.[13]
Treprostinil (Orenitram), as extended release tablets, was approved for medical use in the United States in December 2013.[14]
Treprostinil (Trepulmix) was authorized for medical use in the European Union in April 2020.[6] Trepulmix is a hybrid medicine that is similar to the reference medicine Remodulin.[6] It contains the same active substance, but it is used for treating a different form of pulmonary hypertension.[6]
Treprostinil (Tyvaso DPI), as inhalation powder, was approved for medical use in the United States in May 2022.[15][16]
Treprostinil (Yutrepia), as inhalation powder, was approved for medical use in the United States in June 2025.[5][17][18]
^abcdef"Trepulmix EPAR".European Medicines Agency (EMA). 29 January 2020.Archived from the original on 3 August 2020. Retrieved9 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^Torres F, Rubin LJ (January 2013). "Treprostinil for the treatment of pulmonary arterial hypertension".Expert Review of Cardiovascular Therapy.11 (1):13–25.doi:10.1586/erc.12.160.PMID23259441.S2CID29661141.
Narine L, Hague LK, Walker JH, Vicente C, Schilz R, Desjardins O, et al. (December 2005). "Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension".Current Medical Research and Opinion.21 (12):2007–2016.doi:10.1185/030079905X75104.PMID16368052.S2CID13162585.
Clinical trial numberNCT03399604 for "Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (INSPIRE)" atClinicalTrials.gov
N
Y (what is this?) (verify)